Table 2. Completion of treatment in 210 patients with LA NPC.

Treatment	N (%)
NAC regimens
TPF	62 (29.5)
TP	64 (30.5)
GP	7 (3.3)
FP	73 (34.8)
Other	4 (1.9)
Cycle of NAC
1	40 (19.0)
2	80 (38.1)
3–4	90 (42.9)
CC regimens
Cisplatin	198 (94.3)
Non-cisplatin	12 (5.7)
Cycle of CC
1	76 (36.2)
2	120 (57.1)
≥3	14 (6.7)
Period of CC
Weekly	12 (5.7)
3 weeks	198 (94.3)
AC
No	115 (54.8)
Yes	95 (45.2)
Fractional dose of h-R3
100 mg	23 (11.0)
200 mg	187 (89.0)
Total dose of h-R3
< 1200 mg	60 (28.6)
≥ 1200 mg	150 (71.4)
Cycle of h-R3
< 6 weeks	39 (18.6)
≥ 6 weeks	171 (81.4)

Abbreviations: NAC: neoadjuvant chemotherapy. CC: concurrent chemotherapy. AC: adjuvant chemotherapy. h-R3: nimotuzumab.